Basic Details
| Item | Value |
|---|---|
| Title | Long Merck & Co (MRK) Stock on Measles Resurgence Demand |
| Type | Trading |
| Difficulty | 20 |
| Ideal Capital | 5000 |
| ROI | 27% |
| ETA on ROI | 15 |
| Target Audience | Retail investors, healthcare sector investors, swing traders |
| Target Countries | US (NYSE), accessible globally via brokers |
| Target Demographics | Adults 25-60, with brokerage accounts, interested in thematic/pharma investing |
| Description | Buy shares of Merck & Co. (NYSE: MRK) at current market price (~$110). The company’s M-M-R II vaccine is the leading measles vaccine in the Americas. Expected increase in orders from PAHO and national governments for catch-up campaigns. Set a price target of $140 within 12-18 months, with a stop loss at $95. Position size: $5,000 (approx. 45 shares). Monitor quarterly earnings for vaccine segment growth. |
| Monetization | Capital gains from stock price appreciation; potential dividend yield (~2.5% annual). |
| Pros |
|
| Cons |
|
